109 related articles for article (PubMed ID: 22571234)
1. Side effects of systemic oncological therapies in dermatology.
Zimmer L; Vaubel J; Livingstone E; Schadendorf D
J Dtsch Dermatol Ges; 2012 Jul; 10(7):475-86. PubMed ID: 22571234
[TBL] [Abstract][Full Text] [Related]
2. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
[TBL] [Abstract][Full Text] [Related]
3. Skin toxicity of anti-cancer therapy.
Ulrich J; Hartmann JT; Dörr W; Ugurel S
J Dtsch Dermatol Ges; 2008 Nov; 6(11):959-77. PubMed ID: 18992037
[TBL] [Abstract][Full Text] [Related]
4. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
5. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
[TBL] [Abstract][Full Text] [Related]
6. Advances in the management of cutaneous toxicities of targeted therapies.
Robert C; Sibaud V; Mateus C; Cherpelis BS
Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
[TBL] [Abstract][Full Text] [Related]
7. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
9. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.
Barrios DM; Phillips GS; Freites-Martinez A; Hsu M; Ciccolini K; Skripnik Lucas A; Marchetti MA; Rossi AM; Lee EH; Deng L; Markova A; Myskowski PL; Lacouture ME
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1340-1347. PubMed ID: 31856311
[TBL] [Abstract][Full Text] [Related]
10. [Cutaneous side effects of medical tumor therapy].
Degen A; Alter M; Schenck F; Kapp A; Gutzmer R
Hautarzt; 2011 Jun; 62(6):444-50. PubMed ID: 21503784
[TBL] [Abstract][Full Text] [Related]
11. [Drug reactions caused by chemotherapy agents].
Ehmann LM; Schrumpf H; Gerber PA; Homey B
Hautarzt; 2014 May; 65(5):443-9. PubMed ID: 24820802
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
[TBL] [Abstract][Full Text] [Related]
13. [Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients].
Kähler KC; Hauschild A
Hautarzt; 2009 May; 60(5):433-40. PubMed ID: 19430753
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous side effects of targeted cancer drugs].
Below J; Homey B; Gerber PA
Hautarzt; 2017 Jan; 68(1):12-18. PubMed ID: 27885401
[TBL] [Abstract][Full Text] [Related]
15. Skin reactions to the new biologic anticancer drugs.
Myskowski PL; Halpern AC
Curr Opin Support Palliat Care; 2009 Dec; 3(4):294-9. PubMed ID: 19797958
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
17. [Dermatological side effects in cancer therapy].
Thoms KM; Kretschmer L
J Dtsch Dermatol Ges; 2012 Jul; 10(7):451-2. PubMed ID: 22916350
[No Abstract] [Full Text] [Related]
18. [Side effects of dermato-oncologic therapies].
Hassel JC; Zimmer L
Dermatologie (Heidelb); 2024 Jun; 75(6):466-475. PubMed ID: 38802653
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of targeted therapy in non-small-cell lung cancer management.
Ricciardi S; Tomao S; de Marinis F
Clin Lung Cancer; 2009 Jan; 10(1):28-35. PubMed ID: 19289369
[TBL] [Abstract][Full Text] [Related]
20. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
